J. Goldman & Co’s Karyopharm Therapeutics KPTI Stock Holding History

J. Goldman & Co’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$659K	Buy	+67,500	New	+$586K	0.02%	514
2023 Q4	–	Sell	-8,000	Closed	-$161K	–	412
2023 Q3	$161K	Sell	8,000 -27,983	-78%	-$628K	0.01%	322
2023 Q2	$966K	Buy	+35,983	New	+$1.55M	0.04%	254
2022 Q1	–	Sell	-18,283	Closed	-$1.76M	–	408
2021 Q4	$1.76M	Buy	18,283 +14,435	+375%	+$1.44M	0.1%	214
2021 Q3	$336K	Sell	3,848 -63,149	-94%	-$6.56M	0.02%	298
2021 Q2	$10.4M	Sell	66,997 -21,743	-25%	-$3.16M	0.4%	64
2021 Q1	$14M	Buy	88,740 +71,291	+409%	+$15M	0.45%	51
2020 Q4	$4.05M	Buy	17,449 +5,322	+44%	+$1.23M	0.21%	132
2020 Q3	$2.66M	Buy	12,127 +5,377	+80%	+$1.32M	0.18%	151
2020 Q2	$1.92M	Buy	6,750 +4,864	+258%	+$1.44M	0.12%	163
2020 Q1	$543K	Sell	1,886 -350	-16%	-$96.5K	0.07%	168
2019 Q4	$643K	Sell	2,236 -18,403	-89%	-$3.99M	0.05%	207
2019 Q3	$2.98M	Buy	+20,639	New	+$2.8M	0.22%	123

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Goldman & Co's KPTI Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 67,500 shares worth $659K. The stake represents 0.02% of the portfolio and ranks #514 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in KPTI as recently as Q3 2023.

J. Goldman & Co first reported a position in KPTI in Q3 2019 and has held it in 13 quarters since. The position peaked at $14M in Q1 2021. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

J. Goldman & Co held 67,500 shares of Karyopharm Therapeutics worth $659K as of Q2 2026.
Karyopharm Therapeutics was a new J. Goldman & Co position in Q2 2026.
Karyopharm Therapeutics made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #514 holding.
J. Goldman & Co first reported a position in Karyopharm Therapeutics in Q3 2019 and has held it in 13 quarters since.
J. Goldman & Co's Karyopharm Therapeutics position peaked at $14M in Q1 2021.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.